Venus Medtech (Hangzhou) Inc. is a leading transcatheter heart valve medical device player in China in terms of implantation volume in 2018. The Company's self-developed product, VenusA-Valve, is the first transcather aortic heart valve replacement (“TAVRâ€) product approved by the National Medical Products Administration ("NMPA") and commercialized in China.